Patents by Inventor Mark T. Bilodeau

Mark T. Bilodeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11160871
    Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: November 2, 2021
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Richard Wooster, Kerry Whalen, Patrick Rosaire Bazinet, Mark T. Bilodeau, Sudhakar Kadiyala, Samantha Perino, Beata Sweryda-Krawiec, Rajesh R. Shinde
  • Publication number: 20210169871
    Abstract: The present invention provides improved formulation with reduced tert-butanol levels and/or manufacturing process for drug compounds that form a solvate with tert-butanol. For example, the drug compound may be SDC-TRAP-0063.
    Type: Application
    Filed: April 3, 2019
    Publication date: June 10, 2021
    Applicant: Tarveda Therapeutics, Inc.
    Inventors: Mark T. BILODEAU, Eugene ZHOROV, Rajesh R. SHINDE, Christopher SEARS, Samantha BRADY, Beata SWERYDA-KRAWIEC
  • Publication number: 20210145971
    Abstract: Conjugates of an active agent attached to a targeting moiety, such as at least one HSP90 binding moiety, via a linker, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Application
    Filed: April 3, 2019
    Publication date: May 20, 2021
    Inventors: Mark T. Bilodeau, Benoît Moreau, Sudhakar Kadiyala, Richard Wooster, Brian H. White
  • Publication number: 20210000966
    Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Application
    Filed: December 14, 2018
    Publication date: January 7, 2021
    Inventors: Tyler Cipriani, Benoît Moreau, Mark T. Bilodeau, James M. Quinn, Richard Wooster, Amanda L. Cirello, Samantha Perino, Kerry Whalen, Sudhakar Kadiyala, Brian H. White
  • Publication number: 20200237746
    Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
    Type: Application
    Filed: June 19, 2018
    Publication date: July 30, 2020
    Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
  • Publication number: 20200230247
    Abstract: The invention generally relates to a combination therapy for treating cancer comprising administering at least two distinct therapeutic agents. Components of the combination therapy and methods of using the combination therapy are provided.
    Type: Application
    Filed: June 19, 2018
    Publication date: July 23, 2020
    Inventors: Richard Wooster, Kerry Whalen, Mary Simcox, Leila Alland, Mark T. Bilodeau, Sudhakar Kadiyala, Samantha Perino
  • Publication number: 20200230126
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: June 19, 2018
    Publication date: July 23, 2020
    Inventors: Leila Alland, Christopher Sears, Rajesh R. Shinde, Beata Sweryda-Krawiec, Tsun P. Au Yeung, Mark T. Bilodeau, Sudhakar Kadiyala, Eugene Zhorov, Richard Wooster
  • Publication number: 20200206356
    Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Application
    Filed: February 18, 2020
    Publication date: July 2, 2020
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
  • Publication number: 20200121808
    Abstract: Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 23, 2020
    Inventors: Mark T. Bilodeau, Sudhakar Kadiyala, Rajesh R. Shinde, Brian H. White, Richard Wooster, Benoît Moreau
  • Patent number: 10624967
    Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: April 21, 2020
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
  • Publication number: 20200113877
    Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
  • Publication number: 20200085960
    Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Application
    Filed: December 14, 2017
    Publication date: March 19, 2020
    Inventors: Benoît Moreau, Brian H. White, Mark T. Bilodeau, Mary Simcox, Kerry Whalen, Leila Alland, Richard Wooster, Rajesh R. Shinde
  • Publication number: 20200078468
    Abstract: Conjugates of an active agent attached to a neurotensin receptor-binding targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
    Type: Application
    Filed: April 13, 2017
    Publication date: March 12, 2020
    Inventors: Mark T. Bilodeau, Mary Simcox, Brian H. White, Sudhakar Kadiyala, Richard Wooster
  • Patent number: 10548881
    Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: February 4, 2020
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
  • Publication number: 20200009262
    Abstract: Targeted constructs and pharmaceutical formulations thereof, comprising at least one conjugate of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via an optional internal linker moiety have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the targeted constructs and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Application
    Filed: May 12, 2017
    Publication date: January 9, 2020
    Inventors: Brian H. White, Benoît Moreau, Mark T. Bilodeau, Sudhakar Kadiyala
  • Publication number: 20190365913
    Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker, and particles comprising such conjugates have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Application
    Filed: February 3, 2017
    Publication date: December 5, 2019
    Inventors: Richard Wooster, Sudhakar Kadiyala, Mark T. Bilodeau
  • Publication number: 20190350940
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.
    Type: Application
    Filed: May 16, 2019
    Publication date: November 21, 2019
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Richard Wooster, Benoît Moreau, Kerry Whalen, J. Michael Ramstack, Danielle N. Rockwood, Patrick Lim Soo, Sukhjeet Singh, Tsun P. Au Yeung, Charles-Andre Lemelin, Linda M. Custer
  • Patent number: 10472380
    Abstract: The present disclosure relates to novel platinum compositions having a heterocycle ligand and nanoparticles and methods using such compositions, e.g. for treating cancer.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: November 12, 2019
    Assignee: PLACON THERAPEUTICS, INC.
    Inventors: Adam H. Brockman, Mark T. Bilodeau, Benoît Moreau, Edward R. Lee
  • Publication number: 20190231906
    Abstract: The present invention relates to the use of in vivo contrast agents in medical imaging in order to diagnose and treat disease, and to monitor and assess disease progression following treatment with a nanoparticle therapeutic agent comprising an active pharmaceutical agent. The present invention also relates to modulating nanoparticle tumor concentration by modulating the PEG density of the nanoparticles.
    Type: Application
    Filed: April 11, 2019
    Publication date: August 1, 2019
    Inventors: Sudhakar Kadiyala, Patrick Lim Soo, Mark Iwicki, Craig A. Dunbar, Mark T. Bilodeau, Rajesh R. Shinde, Rossitza G. Alargova, Michelle Dupont
  • Publication number: 20190218241
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one polar moiety as a ligand.
    Type: Application
    Filed: March 26, 2019
    Publication date: July 18, 2019
    Inventors: Mark T. Bilodeau, Benoît Moreau